U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H30O2
Molecular Weight 314.4617
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Progesterone

SMILES

[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CCC4=CC(=O)CC[C@]34C

InChI

InChIKey=RJKFOVLPORLFTN-LEKSSAKUSA-N
InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1

HIDE SMILES / InChI

Molecular Formula C21H30O2
Molecular Weight 314.4617
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/8282004 http://www.rxlist.com/endometrin-drug/clinical-pharmacology.htm

Progesterone is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids of uterine cancer. Progesterone, converted from pregnenolone, also serves as an intermediate in the biosynthesis of gonadal steroid hormones and adrenal corticosteroids. Progesterone is a naturally occurring steroid that is secreted by the ovary, placenta, and adrenal gland. In the presence of adequate estrogen, progesterone transforms a proliferative endometrium into a secretory endometrium. Progesterone is necessary to increase endometrial receptivity for implantation of an embryo. Once an embryo is implanted, progesterone acts to maintain a pregnancy. Progesterone shares the pharmacological actions of the progestins. Progesterone binds to the progesterone and estrogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progesterone will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge. In women who have adequate endogenous estrogen, progesterone transforms a proliferative endometrium into a secretory one. Progesterone is metabolized primarily by the liver largely to pregnanediols and pregnanolones. Pregnanediols and pregnanolones are conjugated in the liver to glucuronide and sulfate metabolites. Progesterone metabolites that are excreted in the bile may be deconjugated and may be further metabolized in the gut via reduction, dehydroxylation, and epimerization. Common progesterone side effects may include: drowsiness, dizziness; breast pain; mood changes; headache; constipation, diarrhea, heartburn; bloating, swelling in your hands or feet; joint pain; hot flashes; or vaginal discharge.

CNS Activity

Curator's Comment: Progesterone readily cross the blood brain barrier (BBB) reducing oedema to barely measurable levels.

Originator

Sources: DOI:10.1159/000301641
Curator's Comment: Using a test based upon Fraenkel and Ancel/ Bouin, Corner and W.M. Allen isolated the hormone progesterone (1929) and first maintained pregnancy with corpus luteum extracts after early ablation of the ovaries rabbit, 1930).

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PROGESTERONE

Approved Use

Is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids of uterine cancer.

Launch Date

1.16933761E12
Primary
PROGESTERONE

Approved Use

Is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids of uterine cancer.

Launch Date

1.16933761E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
60.6 ng/mL
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PROGESTERONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE
food status: UNKNOWN
14.87 ng/mL
90 mg single, vaginal
dose: 90 mg
route of administration: Vaginal
experiment type: SINGLE
co-administered:
PROGESTERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
15.97 ng/mL
90 mg 1 times / day steady-state, vaginal
dose: 90 mg
route of administration: Vaginal
experiment type: STEADY-STATE
co-administered:
PROGESTERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
175.7 ng × h/mL
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PROGESTERONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE
food status: UNKNOWN
296.78 ng × h/mL
90 mg single, vaginal
dose: 90 mg
route of administration: Vaginal
experiment type: SINGLE
co-administered:
PROGESTERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
391.98 ng × h/mL
90 mg 1 times / day steady-state, vaginal
dose: 90 mg
route of administration: Vaginal
experiment type: STEADY-STATE
co-administered:
PROGESTERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
34.8 h
90 mg single, vaginal
dose: 90 mg
route of administration: Vaginal
experiment type: SINGLE
co-administered:
PROGESTERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
45 h
90 mg 1 times / day steady-state, vaginal
dose: 90 mg
route of administration: Vaginal
experiment type: STEADY-STATE
co-administered:
PROGESTERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
400 mg single, vaginal
Dose: 400 mg
Route: vaginal
Route: single
Dose: 400 mg
Sources:
healthy, 32.6 ± 7.3 years
n = 10
Health Status: healthy
Age Group: 32.6 ± 7.3 years
Sex: F
Population Size: 10
Sources:
Other AEs: Drowsiness, Tiredness...
Other AEs:
Drowsiness (1 patient)
Tiredness (1 patient)
Headaches (1 patient)
Faint (1 patient)
Urinary frequency (1 patient)
Sources:
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Co-administed with::
estrogen
Sources:
unhealthy, 50-79 years
Health Status: unhealthy
Age Group: 50-79 years
Sex: F
Sources:
Other AEs: Deep vein thrombosis, Pulmonary embolism...
Other AEs:
Deep vein thrombosis
Pulmonary embolism
Stroke
Myocardial infarction
Dementia
Breast cancer
Sources:
400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
unhealthy, adult
n = 25
Other AEs: Fatigue, Headache...
Other AEs:
Fatigue (8%)
Headache (16%)
Dizziness (24%)
Diarrhea (8%)
Nausea (8%)
Back pain (8%)
Musculoskeletal pain (12%)
Irritability (8%)
Breast pain (16%)
Coughing (8%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Drowsiness 1 patient
400 mg single, vaginal
Dose: 400 mg
Route: vaginal
Route: single
Dose: 400 mg
Sources:
healthy, 32.6 ± 7.3 years
n = 10
Health Status: healthy
Age Group: 32.6 ± 7.3 years
Sex: F
Population Size: 10
Sources:
Faint 1 patient
400 mg single, vaginal
Dose: 400 mg
Route: vaginal
Route: single
Dose: 400 mg
Sources:
healthy, 32.6 ± 7.3 years
n = 10
Health Status: healthy
Age Group: 32.6 ± 7.3 years
Sex: F
Population Size: 10
Sources:
Headaches 1 patient
400 mg single, vaginal
Dose: 400 mg
Route: vaginal
Route: single
Dose: 400 mg
Sources:
healthy, 32.6 ± 7.3 years
n = 10
Health Status: healthy
Age Group: 32.6 ± 7.3 years
Sex: F
Population Size: 10
Sources:
Tiredness 1 patient
400 mg single, vaginal
Dose: 400 mg
Route: vaginal
Route: single
Dose: 400 mg
Sources:
healthy, 32.6 ± 7.3 years
n = 10
Health Status: healthy
Age Group: 32.6 ± 7.3 years
Sex: F
Population Size: 10
Sources:
Urinary frequency 1 patient
400 mg single, vaginal
Dose: 400 mg
Route: vaginal
Route: single
Dose: 400 mg
Sources:
healthy, 32.6 ± 7.3 years
n = 10
Health Status: healthy
Age Group: 32.6 ± 7.3 years
Sex: F
Population Size: 10
Sources:
Breast cancer
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Co-administed with::
estrogen
Sources:
unhealthy, 50-79 years
Health Status: unhealthy
Age Group: 50-79 years
Sex: F
Sources:
Deep vein thrombosis
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Co-administed with::
estrogen
Sources:
unhealthy, 50-79 years
Health Status: unhealthy
Age Group: 50-79 years
Sex: F
Sources:
Dementia
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Co-administed with::
estrogen
Sources:
unhealthy, 50-79 years
Health Status: unhealthy
Age Group: 50-79 years
Sex: F
Sources:
Myocardial infarction
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Co-administed with::
estrogen
Sources:
unhealthy, 50-79 years
Health Status: unhealthy
Age Group: 50-79 years
Sex: F
Sources:
Pulmonary embolism
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Co-administed with::
estrogen
Sources:
unhealthy, 50-79 years
Health Status: unhealthy
Age Group: 50-79 years
Sex: F
Sources:
Stroke
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Co-administed with::
estrogen
Sources:
unhealthy, 50-79 years
Health Status: unhealthy
Age Group: 50-79 years
Sex: F
Sources:
Musculoskeletal pain 12%
400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
unhealthy, adult
n = 25
Breast pain 16%
400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
unhealthy, adult
n = 25
Headache 16%
400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
unhealthy, adult
n = 25
Dizziness 24%
400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
unhealthy, adult
n = 25
Back pain 8%
400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
unhealthy, adult
n = 25
Coughing 8%
400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
unhealthy, adult
n = 25
Diarrhea 8%
400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
unhealthy, adult
n = 25
Fatigue 8%
400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
unhealthy, adult
n = 25
Irritability 8%
400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
unhealthy, adult
n = 25
Nausea 8%
400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
unhealthy, adult
n = 25
OverviewDrug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes
yes
yes
likely (co-administration study)
Comment: Ketoconazole is a known inhibitor of cytochrome P450 3A4, hence these data suggest that ketoconazole or other known inhibitors of this enzyme may increase the bioavailability of progesterone
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
ECC-1 human endometrial cells as a model system to study dioxin disruption of steroid hormone function.
1999 Apr
Estrogen and progesterone distinctively modulate methamphetamine-induced dopamine and serotonin depletions in C57BL/6J mice.
2000
Progesterone synthesized by Schwann cells during myelin formation regulates neuronal gene expression.
2000 Jul
Estrogen activation of the nuclear orphan receptor CAR (constitutive active receptor) in induction of the mouse Cyp2b10 gene.
2000 Nov
Progesterone facilitates chromosome instability (aneuploidy) in p53 null normal mammary epithelial cells.
2000 Nov
Dexamethasone up-regulates type II IL-1 receptor in mouse primary activated astrocytes.
2001 Feb
Human types 1 and 3 3 alpha-hydroxysteroid dehydrogenases: differential lability and tissue distribution.
2001 Feb
Endothelins enhance prostaglandin (PGE(2) and PGF(2alpha)) biosynthesis and release by human luteal cells: evidence of a new paracrine/autocrine regulation of luteal function.
2001 Feb
Action of chicken II GnRH on the human placenta.
2001 Feb
Adenosine triphosphate-evoked cytosolic calcium oscillations in human granulosa-luteal cells: role of protein kinase C.
2001 Feb
Short-term administration of antivascular endothelial growth factor antibody in the late follicular phase delays follicular development in the rhesus monkey.
2001 Feb
Follow-up examination at the age of 15 months of extremely preterm infants after postnatal estradiol and progesterone replacement.
2001 Feb
Enhanced verbal memory in nondemented elderly women receiving hormone-replacement therapy.
2001 Feb
Use of salivary biomarkers in biobehavioral research: cotton-based sample collection methods can interfere with salivary immunoassay results.
2001 Feb
Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay.
2001 Feb 1
Self-augmentation effect of male-specific products on sexually differentiated progesterone metabolism in adult male rat liver microsomes.
2001 Feb 16
Re: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
2001 Feb 7
Concordance in judgments among c-erbB-2 (HER2/neu) overexpression detected by two immunohistochemical tests and gene amplification detected by Southern blot hybridization in breast carcinoma.
2001 Jan
The APC is dispensable for first meiotic anaphase in Xenopus oocytes.
2001 Jan
The octadecaneuropeptide ODN stimulates neurosteroid biosynthesis through activation of central-type benzodiazepine receptors.
2001 Jan
Targeted disruption of luteinizing hormone/human chorionic gonadotropin receptor gene.
2001 Jan
Glucocorticoids regulate plasma membrane potential during rat thymocyte apoptosis in vivo and in vitro.
2001 Jan
Assessment of mechanisms of thyroid hormone action in mouse Leydig cells: regulation of the steroidogenic acute regulatory protein, steroidogenesis, and luteinizing hormone receptor function.
2001 Jan
Biphasic action of prolactin in the regulation of murine Leydig tumor cell functions.
2001 Jan
In vitro regulation of local secretion and contraction of the bovine oviduct: stimulation by luteinizing hormone, endothelin-1 and prostaglandins, and inhibition by oxytocin.
2001 Jan
Granulosa-luteal cell function in vitro and ovarian stimulation protocols.
2001 Jan
Hormones and the brain: more studies.
2001 Jan
Low peripheral blood levels of the immunosuppressive cytokine interleukin 10 (IL-10) at the start of gonadotrophin stimulation indicates increased risk for development of ovarian hyperstimulation syndrome (OHSS).
2001 Jan
Inhibition of ovulation in the rat by a leukotriene B(4) receptor antagonist.
2001 Jan
Female steroid hormones modulate receptors for nerve growth factor in rat dorsal root ganglia.
2001 Jan
Effects of testosterone on production of perivitelline membrane glycoprotein ZPC by granulosa cells of Japanese quail (Coturnix japonica).
2001 Jan
Regulation of progesterone receptors and decidualization in uterine stroma of the estrogen receptor-alpha knockout mouse.
2001 Jan
Changes in plasma inhibin A levels during sexual maturation in the female chicken and the effects of active immunization against inhibin alpha-subunit on reproductive hormone profiles and ovarian function.
2001 Jan
Changes in follicle-stimulating hormone and follicle populations during the ovarian cycle of the common marmoset.
2001 Jan
Excitotoxic lesions of the medial amygdala differentially disrupt prolactin secretory responses in cycling and mated female rats.
2001 Jan
Influence of gender and sex hormones on nicotine acute pharmacological effects in mice.
2001 Jan
Heat-shock factor-1, steroid hormones, and regulation of heat-shock protein expression in the heart.
2001 Jan
Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction.
2001 Jan
The influence of menstrual cycle phase on skeletal muscle contractile characteristics in humans.
2001 Jan 1
Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database.
2001 Jan 1
Functional involvement of Xenopus LIM kinases in progression of oocyte maturation.
2001 Jan 15
Evidence that epithelial and mesenchymal estrogen receptor-alpha mediates effects of estrogen on prostatic epithelium.
2001 Jan 15
In vivo regulation of syndecan-3 expression in the rat uterus by 17 beta-estradiol.
2001 Jan 5
Effects of low-frequency magnetic fields on implantation in rats.
2001 Jan-Feb
Identification of a phosphorylation site in the hinge region of the human progesterone receptor and additional amino-terminal phosphorylation sites.
2001 Mar 16
Patents

Sample Use Guides

5 to 10 mg during 8 consecutive days
Route of Administration: Intramuscular
In Vitro Use Guide
Curator's Comment: As a resule 34% reduction in cell proliferation was observed in the MB468 cells with treatment of P4, as compared with the cells with treatment of vehicle alone. As expected, P4 had no effects on cell proliferation of the parental MB231. However, the treatment of the mPRα stably-expressing MB231 cells with P4 induced a significant reduction of cell proliferation (28.1%). These data suggest that mPRα is also involved in regulating cell proliferation of BPBC cells.
To test whether the female sex hormone controls cell proliferation of MB468 (basal phenotype breast cancers) cells, cell were incubated the with progesterone (P4) (30 ng/ml) for 24 hours.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:16:58 UTC 2023
Edited
by admin
on Fri Dec 15 15:16:58 UTC 2023
Record UNII
4G7DS2Q64Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Progesterone
EP   GREEN BOOK   HSDB   INCI   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INCI   INN  
Official Name English
PREGN-4-ENE-3,20-DIONE
Systematic Name English
PROGESTERONE [EP MONOGRAPH]
Common Name English
PROGESTERONE [JAN]
Common Name English
U 3672
Code English
PROGESTERONE [MI]
Common Name English
PROGESTERONE [HSDB]
Common Name English
PROGESTERONE [GREEN BOOK]
Common Name English
PROGESTERONE [VANDF]
Common Name English
Progesterone [WHO-DD]
Common Name English
PROGESTERONE [WHO-IP]
Common Name English
PROGESTERONE [ORANGE BOOK]
Common Name English
NSC-9704
Code English
CRINONE
Brand Name English
BIJUVA COMPONENT PROGESTERONE
Common Name English
PROGESTERONUM [WHO-IP LATIN]
Common Name English
UTROGESTAN
Brand Name English
ENDOMETRIN
Brand Name English
PROGESTERONE, MICRONIZED
Common Name English
MILPROSA
Brand Name English
PROGESTERONE [USP-RS]
Common Name English
PROMETRIUM
Brand Name English
PROGESTERONE [USP MONOGRAPH]
Common Name English
NSC-64377
Code English
PROGESTERONE COMPONENT OF BIJUVA
Common Name English
PROGESTERONE [MART.]
Common Name English
PROGESTASERT
Brand Name English
PROGESTERONE [INCI]
Common Name English
progesterone [INN]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 664818
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
WHO-VATC QG03FA04
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
NDF-RT N0000005934
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
LIVERTOX 803
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
LOINC 83109-9
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
FDA ORPHAN DRUG 82694
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
CFR 21 CFR 556.540
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
LOINC 83110-7
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
DSLD 4218 (Number of products:3)
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
LOINC 12820-7
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
LOINC 44729-2
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
CFR 21 CFR 522.1940
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
LOINC 24109-1
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
CFR 21 CFR 862.1430
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
WHO-ATC G03FA04
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
LOINC 14890-8
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
EU-Orphan Drug EU/3/13/1101
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
LOINC 17483-9
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
WHO-VATC QG03DA04
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
CFR 21 CFR 310.530
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
NDF-RT N0000005934
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
LOINC 44730-0
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
LOINC 35223-7
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
CFR 21 CFR 862.1620
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
NCI_THESAURUS C2296
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
NDF-RT N0000175601
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
NDF-RT N0000005934
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
LOINC 2838-1
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
LOINC 2839-9
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
WHO-ATC G03DA04
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
FDA ORPHAN DRUG 284809
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
Code System Code Type Description
IUPHAR
2377
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
PRIMARY
CHEBI
17026
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
PRIMARY
RS_ITEM_NUM
1568007
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
PRIMARY
NSC
64377
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
PRIMARY
WIKIPEDIA
PROGESTERONE
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
PRIMARY
CAS
57-83-0
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
PRIMARY
ChEMBL
CHEMBL103
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
PRIMARY
EPA CompTox
DTXSID3022370
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
PRIMARY
FDA UNII
4G7DS2Q64Y
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
PRIMARY
PUBCHEM
5994
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
PRIMARY
DRUG BANK
DB00396
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
PRIMARY
MESH
D011374
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
PRIMARY
SMS_ID
100000090354
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
PROGESTERONE
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
PRIMARY Description: Colourless crystals or a white to slightly yellowish white, crystalline powder; odourless. Solubility: Practically insoluble in water; soluble in 8 parts of ethanol (~750 g/l) TS. Category: Progestational steroid. Storage: Progesterone should be kept in a well-closed container, protected from light. Additional information: Progesterone may exist in 2 polymorphic forms, one of which melts at about 130?C, the other at about 121?C. Definition: Progesterone contains not less than 97.0% and not more than 102.0% of C21H30O2, calculated with reference to the dried substance.
MERCK INDEX
m9159
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
PRIMARY Merck Index
EVMPD
SUB10076MIG
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
PRIMARY
DRUG CENTRAL
2279
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
PRIMARY
ECHA (EC/EINECS)
200-350-6
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
PRIMARY
LACTMED
Progesterone
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
PRIMARY
NCI_THESAURUS
C777
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
PRIMARY
DAILYMED
4G7DS2Q64Y
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
PRIMARY
INN
417
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
PRIMARY
HSDB
3389
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
PRIMARY
NSC
9704
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
PRIMARY
RXCUI
8727
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
PRIMARY
MESH
C400424
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
PRIMARY
RXCUI
259409
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
ALTERNATIVE
WIKIPEDIA
Progesterone (medication)
Created by admin on Fri Dec 15 15:16:58 UTC 2023 , Edited by admin on Fri Dec 15 15:16:58 UTC 2023
PRIMARY
Related Record Type Details
DERIVATIVE -> PARENT
DERIVATIVE -> PARENT
TARGET -> AGONIST
IC50
TARGET -> AGONIST
BINDING
IC50
ANALOGUE->TARGET
TARGET -> AGONIST
BINDING
IC50
DERIVATIVE -> PARENT
ENZYME->SUBSTRATE
Vmax
AGONIST -> TARGET
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY